Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Explaining the poison pill defence which could have derailed Musk’s Twitter bid

The world’s richest man, Elon Musk seems to have prevailed in his $43 billion takeover of Twitter (TWTR:NASDAQ).
Initially though the Twitter board looked to prevent him from gaining ‘creeping’ control of the company by adopting a poison pill strategy which was popularised in the 1980s.
The aim was to stop Musk from increasing his stake by purchasing more shares in the open market. By doing so Musk could effectively have gained control of the company without paying a ‘control premium’.
How would this defence tactic have worked? Also known as a ‘shareholder rights plan’, it aims to dilute an aggressor’s shareholding.
If Musk breached 15% of Twitter’s share capital, the board was threatening to offer existing shareholders an opportunity to buy new shares at a discount to the prevailing price. The new shares would have greater voting rights.
The extra shares issued, which Musk would not have been allowed to purchase, would have increased the total number of shares in issue and reduced Musk’s percentage holding in Twitter. This would in theory would have made it prohibitively expensive for him to increase his stake.
In 2012 activist investor Carl Icahn purchased just under 10% of streaming content provider Netflix (NFLX:NASDAQ). The board immediately adopted the poison pill strategy which Icahn denounced as poor corporate governance.
A FAIRER SYSTEM
Poison pill tactics are not allowed under UK stock exchange rules which are designed to prevent ‘frustrating actions’. The idea is to give power to shareholders rather than a company’s directors.
UK boards must make arguments to convince shareholders not to accept offers from interested parties. Arguably, this is a fairer system because it puts owner’s rights above those of company directors.
The potential downside is it makes UK firms more vulnerable to opportunistic bids which might look attractive in the short term but can undervalue the long-term potential of a business.
However, the UK government protects companies of strategic interest from takeover via a blocking ‘golden share’. This protects BAE Systems (BA.), Rolls Royce (RR.) and some of Babcock International’s (BAB) dockyard assets.
In the Netherlands companies can defend themselves from hostile takeovers by creating a foundation or stichting.
This body issues preferred shares which are priced below the ordinary shares but have greater voting rights. Historically this structure has protected many family-controlled businesses.
In 2015, for example, Dutch pharmaceutical company Mylan (which merged with a division of Pfizer (PFE:NYSE) to create Viatris (VTRS:NASDAQ) in 2020) used this mechanism to fend off an attempted takeover by Israeli rival Teva (TEVA:TASE).
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Feature
- Great buying opportunities from the big tech rout
- The companies able to charge more without hurting demand
- Explaining the poison pill defence which could have derailed Musk’s Twitter bid
- How big property funds have performed and the different ways to invest
- Emerging markets: Views from the experts
- The best and worst first quarter performers in emerging markets
- Why Unilever has a 10.5% stake in this small cap drug developer
Great Ideas
- Strong reasons to buy Strix, a global leader in niche market
- Loungers maintains fast growth despite facing consumer headwinds
- Brookfield and Homeserve in talks as broker says shares could be worth £15
- Asia Dragon Trust goes shopping for stocks amid market sell-off
- Smartly-timed sale and share buyback reveal Spectris’ hidden value
- Why B&M remains a great way to beat the squeeze
News
- Novacyt faces £134.6 million NHS legal claim
- Can consumer-facing firms beat the big squeeze?
- Growth stocks continue to struggle as we reveal stocks at 52-week highs and lows
- Shares in mining companies hurt by Chinese lockdowns and operational issues
- Why language services group RWS could be the latest private equity victim